| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Molecular and Cellular Biology, June 2008, p. 3589-3599, Vol. 28, No. 11
0270-7306/08/$08.00+0 doi:10.1128/MCB.00040-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
,
Department of Oncology, Georgetown University, and Lombardi Comprehensive Cancer Center, Washington, DC 20007,1 Niigata University, Niigata, Japan,2 Keio University, Tokyo, Japan3
Received 9 January 2008/ Returned for modification 6 February 2008/ Accepted 13 March 2008
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
Msi1 was identified originally as a positive regulator of Notch and a cell fate determinant for neuroglial stem cells (13, 49). Notch is activated by sequential proteolytic cleavage of its membrane-associated form to a constitutively active intracellular coactivator (2), whose expression is regulated by Numb and Msi1 (45). Numb promotes ubiquitination of intracellular Notch (40) and interferes with its nuclear translocation (68). Msi1 is an RNA-binding protein that associates with the cis-acting repressor sequences in the 3'-untranslated region of the Numb mRNA to block its translation (29). Msi1 maintains the proliferation of multipotential neural stem cells (45) and is rapidly downregulated in postmitotic neurons (49). It is highly expressed in central nervous system tumors originating from neural stem cells (62, 75). In a similar context, human breast stem cells are enriched in Notch3 (19) and Notch ligands promote the proliferation of epithelial and myoepithelial progenitor cells. Breast LRC and side population cells express Msi1 and intracellular Notch1 and exhibit a CK19+ estrogen receptor+ phenotype with progenitor cell morphology (14). Although Msi1 appears to be a putative breast stem cell marker, little is known about its functional role in mammary gland development and in stem/progenitor cell self-renewal.
Here we show that Msi1 drives the proliferation of mammary progenitor cells by an autocrine process associated with increased proliferin-1 (PLF1) and reduced Dickkopf-3 (DKK3) secretion, which results in extracellular signal-regulated kinase (ERK) phosphorylation, downregulation of p21Cip1, and enhanced Wnt and Notch signaling. Additionally, Msi1 modulates the expression of a number of genes associated with the cell cycle, development, and cell adhesion. These results are the first to document a mechanistic role for Msi1 in mammary stem/progenitor cell expansion.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Viral transduction.
Flag-tagged Msi1 cDNA was prepared and subcloned into retroviral vector pCMV/hyg, which was generated by replacement of the Tet on/off control element in pRevTRE (Clontech, Inc., Palo Alto, CA) with the cytomegalovirus promoter from pRc/CMV (Invitrogen) (76). 293T cells were cotransfected with either pCMV/hyg or pCMV/Msi1 and ecotropic retroviral vector pSV-
–-E-MLV. After 48 h, the supernatant was collected, mixed with an equal volume of fresh DMEM-F12 medium plus 2x supplement in the presence of 4 µg/ml Polybrene, and added to COMMA-1D cells. After four rounds of infection, COMMA-1D cells were selected in hygromycin for 2 weeks, and the expression of Flag-Msi1 was confirmed by Western blotting with anti-Flag antibody and anti-Msi1 antibody.
Growth assay. Cells were seeded into a 96-well plate at 3,000 cells/well in 200 µl medium, and growth was determined 24 to 72 h later by sulforhodamine B staining (53, 72).
Colony assay. Colony formation was performed by seeding 3,000 cells into a 100-mm dish containing a 50:50 mixture of fresh medium and conditioned medium from COMMA-1D cells transduced with either empty vector (COMMA/Vect) or Msi1 (COMMA/Msi1) (76). The number of colonies with >50 cells was determined after 8 days.
Western blots. Western blotting was performed using the Criterion system (Bio-Rad, Hercules, CA). Cells were lysed on ice in lysis buffer (76), and protein concentration was determined using the bicinchoninic acid protein assay reagent kit (Pierce, Rockford, IL). Protein (20 µg) was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Bio-Rad) and transferred to a polyvinylidene difluoride membrane (Amersham Biosciences, Piscataway, NJ). Proteins were detected with the appropriate primary antibody (see Table S1 in the supplemental material) using horseradish peroxidase-linked secondary antibodies and visualized by chemiluminescence (Amersham Biosciences, Piscataway, NJ). In some instances, pERK was measured after COMMA/Vect or COMMA/Msi1 cells were treated for 48 h with U0126 (Sigma-Aldrich Chemical Co., St. Louis, MO). COMMA/Msi1 cells were also treated for 4 h with 0.3, 1, and 3 ng/ml pertussis toxin (List Biological Laboratories, Inc., Campbell, CA), and cells were harvested for Western analysis of pERK.
Proliferin depletion from conditioned medium. Conditioned medium from COMMA/Msi1 cells was concentrated 2.5-fold by centrifugation through a Centricon YM-10 spin filter with a 10-kDa cutoff (Millipore Corp.). Concentrated medium was then incubated overnight at 4°C with 4 µl PLF1 monoclonal antibody 209 (kindly provided by Daniel Linzer, Northwestern University, Evanston, IL) or with control immunoglobulin G (IgG). Protein G-Sepharose (40 µl) preequilibrated with phosphate-buffered saline (PBS) was added, and after 30 min, samples were centrifuged at 2,500 x g for 10 min and removal of PLF1 was confirmed by Western blotting. Cells were seeded into a 24-well plate in medium containing 0.2 ml PLF1-depleted conditioned medium or control medium, and after 4 h, pERK was measured by Western blotting.
Fluorescence microscopy. Cells were grown in chamber slides (Lab-Tek, Hatfield, PA), fixed in 100% cold methanol for 10 min, and stored at –20°C. Fixed cells were stained with primary antibodies overnight at 4°C, followed by incubation with either fluorescein isothiocyanate- or phycoerythrin-conjugated secondary antibody (Invitrogen, Carlsbad, CA). Cells were counterstained with 4',6'-diamidino-2-phenylindole (DAPI) (Invitrogen). A Nikon E600 Epi-Fluorescent microscope was used for image capture.
Quantitative real-time PCR (qRT-PCR).
Total RNA was extracted using an RNeasy minikit (Qiagen, Valencia, CA) by following the manufacturer's protocol. Genomic DNA was digested by incubation with RNase-free DNase for 15 min at room temperature. One microgram of RNA was reverse transcribed in a total volume of 20 µl using the Omniscript RT kit (Qiagen). PCR was performed in triplicate in an ABI-Prism 7700 instrument (Applied Biosystems, Foster City, CA) using Sybr green I detection (Qiagen) according to the manufacturer's protocol. Amplification using the appropriate primers (see Table S3 in the supplemental material) was confirmed by ethidium bromide staining of the PCR products on an agarose gel. The expression of each target gene was normalized to the expression of 18S RNA and is presented as the ratio of the target gene to 18S RNA, expressed as 2–
Ct, where Ct is the threshold cycle and
Ct = CtTarget – Ct18S.
Gene microarray analysis. Total RNA was extracted using an RNeasy minikit (Qiagen) by following the manufacturer's protocol. cRNA synthesis was carried out using the Affymetrix (Santa Clara, CA) protocol with minor modifications as described previously (73). Biotin-labeled cRNA was fragmented at 94°C for 35 min and used for hybridization overnight to an Affymetrix mouse 430A2.0 GeneChip representing approximately 14,000 annotated mouse genes by the Macromolecular Analysis Shared Resource. GeneChips were scanned using an Agilent gene array scanner, and grid alignment and raw data generation were performed with Affymetrix GeneChip operating software, version 1.1. The expression levels of genes that were either increased or decreased at least twofold in both experiments were clustered hierarchically by CIMiner software (National Cancer Institute, NIH). Gene ontology analysis was performed by the L2L microarray analysis tool (http://depts.washington.edu/l2l/) (42). For the results of these analyses, see Table S1 in the supplemental material.
Flow cytometry. For surface antigen detection, cells were suspended to a concentration of 0.5 x 106 to 1 x 106 cells/ml in ice-cold PBS containing 3% fetal bovine serum, 2 µg/106 cells of primary antibody or control isotype antibody conjugated to fluorescein isothiocyanate or phycoerythrin (see Table S2 in the supplemental material) was added, and cells were incubated on ice for 60 min in the dark. Cells were washed three times by centrifugation at 400 x g for 5 min and resuspended in ice-cold PBS containing 3% fetal bovine serum. Stained cells were detected by FACScan and analyzed with FCS Express V3 software (De Novo Software, Ontario, Canada).
Luciferase reporter assays. COMMA/Vect or COMMA/Msi1 cells were grown in 24-well plates in DMEM-F12 medium containing 5% fetal calf serum. After 24 h, medium was replaced with DMEM-F12 containing 5% delipidated fetal calf serum (Sigma-Aldrich Chemical Co.), and cells were transfected using Lipofectamine Plus (Invitrogen) and the reporter plasmids. pTopFlash (Invitrogen) and CBF1-luciferase (provided by Tony Cappobianco, Wistar Research Institute, Philadelphia, PA). pTopFlash was used to measure β-catenin/T-cell factor (TCF)-dependent transcription, and CBF1-luciferase was used to measure Notch/CSL-dependent transcription. Luciferase activity was measured with the Dual-Luciferase assay system (Promega, Madison, WI).
RNA interference assays. Three short hairpin RNAs (shRNAs) targeting either PLF1 or DKK3 were designed in collaboration with Xiao Zeng, SuperArray Biosciences, Frederick, MD, and cloned into an expression vector for either transient expression (reporter assay and qRT-PCR analyses) or stable expression (pERK Western analysis) after selection with G418 for 2 weeks. For reporter assays, 4 x 104 COMMA/Vect or COMMA/Msi1 cells were seeded into each well of a 24-well plate in 1 ml medium 1 day before transfection. When cells were 70% confluent, they were transfected with 0.2 µg shRNA per well using Lipofectamine Plus reagent. After 24 h, cells were transfected with 0.2 µg of either Topflash or CBF1-luciferase plasmid DNA, and luciferase activity was measured after 24 h using the Dual-Luciferase reporter assay system (Promega, Madison, WI). Although all shRNAs tested gave similar results, those with the greatest activity were GCAAGCTTACCTCCCAACTAT for mouse shDKK3 and AAGAAGCCCTGCCTGGTTCTT for mouse shPLF1; GGAATCTCATTCGATGCATAC was used as a negative control. All experiments were repeated in triplicate.
| RESULTS |
|---|
|
|
|---|
|
|
Msi1 stimulates proliferation, increases PLF1 secretion, and reduces DKK3 secretion in an autocrine fashion. The growth of COMMA/Msi1 cells on plastic was far greater than that of control cells (Fig. 3A), but the cells did not exhibit anchorage-independent growth in soft agar (results not shown), suggesting that Msi1 expression per se does not lead to transformation. To determine if an autocrine mechanism was associated with proliferation, levels of colony formation by the two cell lines were compared using a 50:50 mixture of fresh medium and conditioned medium from either COMMA/Msi1 or COMMA/Vect cells (Fig. 3B). After 8 days in culture, COMMA/Msi1 cells exhibited increased colony formation compared to control cells when grown in conditioned medium from control cells; however, the growth of both cell lines was markedly stimulated by conditioned medium from COMMA/Msi1 cells. Since the PLF1 and DKK3 genes exhibited the greatest changes among candidate growth-stimulatory and -inhibitory genes, respectively, changes in their expression were examined by qRT-PCR, as well as Western analysis of the conditioned medium (Fig. 3C). Gene microarray and qRT-PCR analyses indicated 17- and 38-fold increases in PLF1 expression, respectively (Fig. 3C), which coincided with a 15- to 20-fold reduction in expression of DKK3 (Fig. 3C, left). Western blot analysis of concentrates of conditioned medium from COMMA/Msi1 cells indicated an increase in PLF (the antibody does not distinguish between the three PLF homologs, which differ by 3 or 4 amino acids) and the disappearance of DKK3, which was readily detectable in the conditioned medium from control cells (Fig. 3C, right).
|
|
COMMA/Msi1 cells expressed greater cyclin D1 and D2 levels than control cells (Fig. 4A), which is consistent with β-catenin/TCF (52) and Notch (48) pathway activation and reduced GSK3β activation, which normally promotes the phosphorylation, ubiquitination, and proteasomal degradation of β-catenin (66) and intracellular Notch (21). Therefore, Notch and β-catenin/TCF signaling was assessed by reporter gene analysis. CBF1/Notch reporter activity increased sevenfold in COMMA/Msi1 cells (Fig. 5A, top) and correlated with increased expression of Notch1, its target the Hes1 gene, and the Notch ligands Delta1 and Jagged1, as determined by qRT-PCR (Fig. 5A, middle). Importantly, CBF1 activity was dependent on ERK activation, as shown by the inhibitory effect of U0126 (Fig. 5A, bottom). As a measure of β-catenin/TCF activation, nuclear localization of β-catenin was determined by immunofluorescence (Fig. 5B). Increased nuclear localization of β-catenin in Msi1-expressing cells correlated with increased β-catenin/TCF-dependent reporter gene activity (Fig. 5C, top). As with Notch reporter gene activity, β-catenin/TCF reporter gene activity in COMMA/Msi1 cells was preferentially inhibited by U0126 (Fig. 5, bottom), indicating dependence on MEK/ERK activation.
|
40%), these results provide strong support for the involvement of DKK3 and PLF1 signaling downstream of Msi1-mediated changes in proliferation, progenitor cell expansion, and Wnt and Notch pathway activation. | DISCUSSION |
|---|
|
|
|---|
Msi1 cells also express a higher percentage of cytokeratin (CK) markers, indicative of basal cells (a mixture of stem and progenitor cells), such as CK6 and CK19, and are double positive for CK14/CK18. CK6 is abundant in stem and basal cells (7, 17, 60, 69) and has been linked to proliferation of the alveolar epithelium and activation of the Wnt pathway (37). CK19 is expressed in luminal progenitor cells that give rise to CK14+ basal cells (46, 56), and double-positive CK14/CK18 cells exhibit bipotential progenitor cell characteristics (7). These results are also consistent with the contention that Msi promotes the expansion of early progenitor cells.
Msi1 expression increased Wnt pathway activation, as demonstrated by increased β-catenin/TCF-dependent transcription and β-catenin nuclear localization. The Wnt pathway drives alveolar proliferation in MMTV-Wnt1 (5) and MMTV-
N89β-catenin (30) transgenic mice, and targeting of
N89β-catenin to mammary basal cells by the CK5 promoter produces precocious end bud development (61). Expansion of mammary basal cells with characteristic CK6/CK14 expression was also noted in mice with increased Notch pathway activation (7). These results are consistent with our findings that Msi1 activates progenitor cell expansion via activation of the Wnt and Notch pathways.
Msi1 expression in mammary epithelial cells resulted in downregulation of the cyclin-dependent kinase inhibitor p21Cip1, which is in agreement with p21Cip1 being a translational target of Msi1 (3). p21Cip1 is thought to function as a rheostat to maintain a balance between stem cell quiescence and stem cell exhaustion resulting from increased cell cycle entry (9, 32). Reduced p21Cip1 expression due to Msi1 is consistent with actively cycling progenitor cells and their increased proliferation in vitro.
Gene profiling identified increased PLF1 expression, as well as an equally large reduction of DKK3, a secreted Wnt pathway inhibitor, and these changes were confirmed to occur in the conditioned medium of COMMA/Msi1 cells. The PLF1 gene is one of three highly homologous genes related to the prolactin gene family, mapping to a single locus on mouse chromosome 13 (71). PLF1 is a ligand for the Gi protein-coupled IGF2R (25, 36), which mediates prolactin-induced alveolar development in the mammary gland through activation of ERK and Jak2 (6, 27). Receptor activation by PLF1 activates ERK (20, 25) and transcription factor AP-1 (63) and is blocked by pertussis toxin (20, 25), which catalyzes ADP-ribosylation of the Gi
subunit to prevent its interaction with cell membrane receptors (8). This mechanism is consistent with the inhibitory effect of pertussis toxin on PLF1-mediated ERK activation by COMMA/Msi-conditioned medium, as well as inhibition of ERK activation by PLF1 depletion from COMMA/Msi1-conditioned medium. This interrelationship was further confirmed by shRNA-mediated reduction of PLF1 in COMMA/Msi1 cells. IGF2R stimulation is known to increase β-catenin nuclear localization and epithelial-mesenchymal transition (41), which are associated with growth and invasion (12). Particularly relevant is the finding that IGF2 signaling increased the number of Msi1-positive intestinal stem/progenitor cells and their susceptibility to tumorigenesis (50). Also pertinent to our findings is the identification of the PLF2 and PLF3 genes as Wnt-1 target genes (38). Although Wnt signaling has not previously been shown to increase PLF1 expression, the fact that the three PLF genes are transcribed from a single locus suggests that they are regulated in a similar manner. We have previously found that PLF1 expression is upregulated in mammary tumors with basal cell characteristics (73, 74), and PLF2 has been shown to expand mouse hematopoietic stem cells ex vivo (11). It is therefore likely that PLF1 plays a similar role in the expansion of mammary progenitor cells through Msi1. This is further suggested by RNA interference, where reduction of PLF1 decreased Wnt and Notch reporter activity. These results therefore support a role for PLF1 in Msi1-mediated activation of the Wnt and Notch pathways and in mammary progenitor cell expansion.
DKK3 was identified as negative regulator downstream of Msi1 signaling. DKK3 (also known as REIC [reduced expression in immortalized cells]) is one of four homologous secreted proteins (34) that function as tumor suppressors to block proliferation (44). DKK1 and DKK2, but not DKK3, block Wnt pathway activation by binding to the Wnt coreceptor LRP5/6 (39), but DKK3 also prevents nuclear localization of β-catenin by an unknown mechanism (26). RNA interference in control cells showed that DKK3 negatively regulated β-catenin/TCF and CBF1 activation, producing a phenotype which resembled the phenotype resulting from Msi1 expression. DKK3 expression in lung, prostate, and liver tumor cells induced apoptosis (1, 28, 65) and disrupted acinar morphogenesis and the growth of prostate tumor cells (31). Reduced expression of DKK3 in melanoma cells correlated with loss of cell adhesion, increased invasion, upregulation of the transcriptional repressor Snail-1 (47), and reduction of E-cadherin (35), suggesting that loss of DKK3 promoted epithelial-mesenchymal transition. However, gene profiling and Western analysis of COMMA/Msi1 cells did not indicate a reduction in E-cadherin expression (results not shown), suggesting that this mechanism is not operative. Overall, our findings suggest that reduction of DKK3 is responsible, in part, for increased proliferation upstream of Wnt and Notch pathway activation.
Notch-mediated transformation was shown previously to be downstream of Ras and ERK activation (22), and our data also suggest such a relationship. Msi1 activated Wnt signaling that was dependent on ERK activation, as shown by the inhibitory effect of U0126 on proliferation and β-catenin/TCF gene transcription. ERK activation occurred downstream of PLF1, and inhibition of PLF1 signaling by pertussis toxin inhibited ERK. One mechanism common to activation of both Notch and Wnt signaling is inhibition of GSK3β by ERK phosphorylation, which primes GSK3β for inactivation (18). GSK3β in its activated state phosphorylates and promotes ubiquitination and proteasomal degradation of β-catenin (66) and intracellular Notch (21), providing a link between PLF1, ERK, and Wnt and Notch pathway activation.
PLF1-mediated ERK signaling correlated with the CD24hi CD29+ progenitor cell phenotype observed in COMMA/Msi1 cells. CD24 is highly expressed in invasive tumor cells (4) and mediates its effects through integrin β1, the subunit expressed by CD29, which itself is upregulated through the Ras/ERK pathway (43). CD24 expression is linked to IGF2 signaling through the IGF2R, the same receptor for which PLF1 serves as a ligand. Importantly, deletion of the IGF2 gene in glioblastoma cells reduced CD24 expression by 90% and suppressed invasion (23).
In summary, our studies suggest a novel signaling mechanism, depicted in Fig. 6, where Msi1 increases PLF1 secretion and reduces DKK3 expression, leading to increased Notch and Wnt pathway activation through ERK activation. Inhibition of p21Cip1 expression by Msi1 works cooperatively with Notch and Wnt pathway activation to promote cyclin D1- and D2-dependent protein kinase activation and G1/S transit through the cell cycle. Inhibition of Numb by Msi1 maintains Notch activity and transcription of its downstream ligand and effector genes, which also promote proliferation. The net result of these processes is the stimulation of progenitor cell expansion and proliferation, conditions likely to promote mammary gland development and provide a new paradigm for progenitor cell signaling in the mammary gland.
|
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
Published ahead of print on 24 March 2008. ![]()
Supplementary material for this article may be found at http://mcb.asm.org/. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Baron, M. 2003. An overview of the Notch signalling pathway. Semin. Cell Dev. Biol. 14:113-119.[CrossRef][Medline]
3. Battelli, C., G. N. Nikopoulos, J. G. Mitchell, and J. M. Verdi. 2006. The RNA-binding protein Musashi-1 regulates neural development through the translational repression of p21WAF-1. Mol. Cell. Neurosci. 31:85-96.[CrossRef][Medline]
4. Baumann, P., N. Cremers, F. Kroese, G. Orend, R. Chiquet-Ehrismann, T. Uede, H. Yagita, and J. P. Sleeman. 2005. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res. 65:10783-10793.
5. Bocchinfuso, W. P., W. P. Hively, J. F. Couse, H. E. Varmus, and K. S. Korach. 1999. A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha. Cancer Res. 59:1869-1876.
6. Brisken, C., A. Ayyannan, C. Nguyen, A. Heineman, F. Reinhardt, J. Tan, S. K. Dey, G. P. Dotto, R. A. Weinberg, and T. Jan. 2002. IGF-2 is a mediator of prolactin-induced morphogenesis in the breast. Dev. Cell 3:877-887.[CrossRef][Medline]
7. Buono, K. D., G. W. Robinson, C. Martin, S. Shi, P. Stanley, K. Tanigaki, T. Honjo, and L. Hennighausen. 2006. The canonical Notch/RBP-J. signaling pathway controls the balance of cell lineages in mammary epithelium during pregnancy. Dev. Biol. 293:565-580.[CrossRef][Medline]
8. Burns, D. L. 1988. Subunit structure and enzymic activity of pertussis toxin. Microbiol. Sci. 5:285-287.[Medline]
9. Cheng, T., N. Rodrigues, H. Shen, Y. Yang, D. Dombkowski, M. Sykes, and D. T. Scadden. 2000. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 287:1804-1808.
10. Chepko, G., and G. H. Smith. 1999. Mammary epithelial stem cells: our current understanding. J. Mammary Gland Biol. Neoplasia 4:35-52.[CrossRef][Medline]
11. Choong, M. L., A. C. Tan, B. Luo, and H. F. Lodish. 2003. A novel role for proliferin-2 in the ex vivo expansion of hematopoietic stem cells. FEBS Lett. 550:155-162.[CrossRef][Medline]
12. Christofori, G. 2006. New signals from the invasive front. Nature 441:444-450.[CrossRef][Medline]
13. Clarke, R. B., E. Anderson, A. Howell, and C. S. Potten. 2003. Regulation of human breast epithelial stem cells. Cell Prolif. 36(Suppl. 1):45-58.[Medline]
14. Clarke, R. B., K. Spence, E. Anderson, A. Howell, H. Okano, and C. S. Potten. 2005. A putative human breast stem cell population is enriched for steroid receptor-positive cells. Dev. Biol. 277:443-456.[CrossRef][Medline]
15. Danielson, K. G., C. J. Oborn, E. M. Durban, J. S. Butel, and D. Medina. 1984. Epithelial mouse mammary cell line exhibiting normal morphogenesis in vivo and functional differentiation in vitro. Proc. Natl. Acad. Sci. USA 81:3756-3760.
16. DeOme, K. B., L. J. Faulkin, H. A. Bern, and P. B. Blair. 1959. Development of mammary tumors from hyperplastic alveolar nodules transplanted into gland-free mammary fat pads of female C3H mice. Cancer Res. 19:515-520.
17. Deugnier, M. A., M. M. Faraldo, J. Teuliere, J. P. Thiery, D. Medina, and M. A. Glukhova. 2006. Isolation of mouse mammary epithelial progenitor cells with basal characteristics from the Comma-Dbeta cell line. Dev. Biol. 293:414-425.[CrossRef][Medline]
18. Ding, Q., W. Xia, J. C. Liu, J. Y. Yang, D. F. Lee, J. Xia, G. Bartholomeusz, Y. Li, Y. Pan, Z. Li, R. C. Bargou, J. Qin, C. C. Lai, F. J. Tsai, C. H. Tsai, and M. C. Hung. 2005. Erk associates with and primes GSK-3β for its inactivation resulting in upregulation of beta-catenin. Mol. Cell 19:159-170.[CrossRef][Medline]
19. Dontu, G., W. M. Abdallah, J. M. Foley, K. W. Jackson, M. F. Clarke, M. J. Kawamura, and M. S. Wicha. 2003. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17:1253-1270.
20. El-Shewy, H. M., M. H. Lee, L. M. Obeid, A. A. Jaffa, and L. M. Luttrell. 2007. The insulin-like growth factor type 1 and insulin-like growth factor type 2/mannose-6-phosphate receptors independently regulate ERK1/2 activity in HEK293 cells. J. Biol. Chem. 282:26150-26157.
21. Espinosa, L., J. Ingles-Esteve, C. Aguilera, and A. Bigas. 2003. phosphorylation by glycogen synthase kinase-3 beta down-regulates Notch activity, a link for Notch and Wnt pathways. J. Biol. Chem. 278:32227-32235.
22. Fitzgerald, K., A. Harrington, and P. Leder. 2000. Ras pathway signals are required for notch-mediated oncogenesis. Oncogene 19:4191-4198.[CrossRef][Medline]
23. Fukushima, T., T. Tezuka, T. Shimomura, S. Nakano, and H. Kataoka. 2007. Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24. J. Biol. Chem. 282:18634-18644.
24. Glazer, R. I., X. Wang, H. Yuan, and Y. Yin. 2007. Mammary stem and progenitor cell regulation. Cancer Biomark. 3:171-181.[Medline]
25. Groskopf, J. C., L. J. Syu, A. R. Saltiel, and D. I. Linzer. 1997. Proliferin induces endothelial cell chemotaxis through a G protein-coupled, mitogen-activated protein kinase-dependent pathway. Endocrinology 138:2835-2840.
26. Hoang, B. H., T. Kubo, J. H. Healey, R. Yang, S. S. Nathan, E. A. Kolb, B. Mazza, P. A. Meyers, and R. Gorlick. 2004. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res. 64:2734-2739.
27. Hovey, R. C., J. Harris, D. L. Hadsell, A. V. Lee, C. J. Ormandy, and B. K. Vonderhaar. 2003. Local insulin-like growth factor-II mediates prolactin-induced mammary gland development. Mol. Endocrinol. 17:460-471.
28. Hsieh, S. Y., P. S. Hsieh, C. T. Chiu, and W. Y. Chen. 2004. Dickkopf-3/REIC functions as a suppressor gene of tumor growth. Oncogene 23:9183-9189.[Medline]
29. Imai, T., A. Tokunaga, T. Yoshida, M. Hashimoto, K. Mikoshiba, G. Weinmaster, M. Nakafuku, and H. Okano. 2001. The neural RNA-binding protein Musashi1 translationally regulates mammalian numb gene expression by interacting with its mRNA. Mol. Cell. Biol. 21:3888-3900.
30. Imbert, A., R. Eelkema, S. Jordan, H. Feiner, and P. Cowin. 2001. Delta N89 beta-catenin induces precocious development, differentiation, and neoplasia in mammary gland. J. Cell Biol. 153:555-568.
31. Kawano, Y., M. Kitaoka, Y. Hamada, M. M. Walker, J. Waxman, and R. M. Kypta. 2006. Regulation of prostate cell growth and morphogenesis by Dickkopf-3. Oncogene 25:6528-6537.[CrossRef][Medline]
32. Kippin, T. E., D. J. Martens, and D. van der Kooy. 2005. p21 loss compromises the relative quiescence of forebrain stem cell proliferation leading to exhaustion of their proliferation capacity. Genes Dev. 19:756-767.
33. Kordon, E. C., and G. H. Smith. 1998. An entire functional mammary gland may comprise the progeny from a single cell. Development 125:1921-1930.[Abstract]
34. Krupnik, V. E., J. D. Sharp, C. Jiang, K. Robison, T. W. Chickering, L. Amaravadi, D. E. Brown, D. Guyot, G. Mays, K. Leiby, B. Chang, T. Duong, A. D. Goodearl, D. P. Gearing, S. Y. Sokol, and S. A. McCarthy. 1999. Functional and structural diversity of the human Dickkopf gene family. Gene 238:301-313.[CrossRef][Medline]
35. Kuphal, S., S. Lodermeyer, F. Bataille, M. Schuierer, B. H. Hoang, and A. K. Bosserhoff. 2006. Expression of Dickkopf genes is strongly reduced in malignant melanoma. Oncogene 25:5027-5036.[CrossRef][Medline]
36. Lee, S. J., and D. Nathans. 1988. Proliferin secreted by cultured cells binds to mannose 6-phosphate receptors. J. Biol. Chem. 263:3521-3527.
37. Li, Y., B. Welm, K. Podsypanina, S. Huang, M. Chamorro, X. Zhang, T. Rowlands, M. Egeblad, P. Cowin, Z. Werb, L. K. Tan, J. M. Rosen, and H. E. Varmus. 2003. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc. Natl. Acad. Sci. USA 100:15853-15858.
38. Longo, K. A., J. A. Kennell, M. J. Ochocinska, S. E. Ross, W. S. Wright, and O. A. MacDougald. 2002. Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factors. J. Biol. Chem. 277:38239-38244.
39. Mao, B., W. Wu, Y. Li, D. Hoppe, P. Stannek, A. Glinka, and C. Niehrs. 2001. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 411:321-325.[CrossRef][Medline]
40. McGill, M. A., and C. J. McGlade. 2003. Mammalian numb proteins promote Notch1 receptor ubiquitination and degradation of the Notch1 intracellular domain. J. Biol. Chem. 278:23196-23203.
41. Morali, O. G., V. Delmas, R. Moore, C. Jeanney, J. P. Thiery, and L. Larue. 2001. IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene 20:4942-4950.[CrossRef][Medline]
42. Newman, J. C., and A. M. Weiner. 2005. L2L: a simple tool for discovering the hidden significance in microarray expression data. Genome Biol. 6:R81.[CrossRef][Medline]
43. Ng, T., D. Shima, A. Squire, P. I. Bastiaens, S. Gschmeissner, M. J. Humphries, and P. J. Parker. 1999. PKC
regulates β1 integrin-dependent cell motility through association and control of integrin traffic. EMBO J. 18:3909-3923.[CrossRef][Medline]
44. Niehrs, C. 2006. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 25:7469-7481.[CrossRef][Medline]
45. Okano, H., T. Imai, and M. Okabe. 2002. Musashi: a translational regulator of cell fate. J. Cell Sci. 115:1355-1359.
46. Pechoux, C., T. Gudjonsson, L. Ronnov-Jessen, M. J. Bissell, and O. W. Petersen. 1999. Human mammary luminal epithelial cells contain progenitors to myoepithelial cells. Dev. Biol. 206:88-99.[CrossRef][Medline]
47. Poser, I., D. Dominguez, A. G. de Herreros, A. Varnai, R. Buettner, and A. K. Bosserhoff. 2001. Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor Snail. J. Biol. Chem. 276:24661-24666.
48. Ronchini, C., and A. J. Capobianco. 2001. Induction of cyclin D1 transcription and CDK2 activity by Notchic: implication for cell cycle disruption in transformation by Notchic. Mol. Cell. Biol. 21:5925-5934.
49. Sakakibara, S., T. Imai, K. Hamaguchi, M. Okabe, J. Aruga, K. Nakajima, D. Yasutomi, T. Nagata, Y. Kurihara, S. Uesugi, T. Miyata, M. Ogawa, K. Mikoshiba, and H. Okano. 1996. Mouse-Musashi-1, a neural RNA-binding protein highly enriched in the mammalian CNS stem cell. Dev. Biol. 176:230-242.[CrossRef][Medline]
50. Sakatani, T., A. Kaneda, C. A. Iacobuzio-Donahue, M. G. Carter, S. de Boom Witzel, H. Okano, M. S. Ko, R. Ohlsson, D. L. Longo, and A. P. Feinberg. 2005. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 307:1976-1978.
51. Shackleton, M., F. Vaillant, K. J. Simpson, J. Stingl, G. K. Smyth, M. L. Asselin-Labat, L. Wu, G. J. Lindeman, and J. E. Visvader. 2006. Generation of a functional mammary gland from a single stem cell. Nature 439:84-88.[CrossRef][Medline]
52. Shtutman, M., J. Zhurinsky, I. Simcha, C. Albanese, M. D'Amico, R. Pestell, and A. Ben-Ze'ev. 1999. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc. Natl. Acad. Sci. USA 96:5522-5527.
53. Skehan, P., R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J. T. Warren, H. Bokesch, S. Kenney, and M. R. Boyd. 1990. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82:1107-1112.
54. Sleeman, K. E., H. Kendrick, A. Ashworth, C. M. Isacke, and M. J. Smalley. 2006. CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Res. 8:R7.[CrossRef][Medline]
55. Sleeman, K. E., H. Kendrick, D. Robertson, C. M. Isacke, A. Ashworth, and M. J. Smalley. 2007. Dissociation of estrogen receptor expression and in vivo stem cell activity in the mammary gland. J. Cell Biol. 176:19-26.
56. Smalley, M. J., J. Titley, H. Paterson, N. Perusinghe, C. Clarke, and M. J. O'Hare. 1999. Differentiation of separated mouse mammary luminal epithelial and myoepithelial cells cultured on EHS matrix analyzed by indirect immunofluorescence of cytoskeletal antigens. J. Histochem. Cytochem. 47:1513-1524.
57. Smith, G. H. 1996. Experimental mammary epithelial morphogenesis in an in vivo model: evidence for distinct cellular progenitors of the ductal and lobular phenotype. Breast Cancer Res. Treat. 39:21-31.[CrossRef][Medline]
58. Smith, G. H. 2005. Label-retaining epithelial cells in mouse mammary gland divide asymmetrically and retain their template DNA strands. Development 132:681-687.
59. Smith, G. H., and D. Medina. 1988. A morphologically distinct candidate for an epithelial stem cell in mouse mammary gland. J. Cell Sci. 90(Pt. 1):173-183.
60. Smith, G. H., T. Mehrel, and D. R. Roop. 1990. Differential keratin gene expression in developing, differentiating, preneoplastic, and neoplastic mouse mammary epithelium. Cell Growth Differ. 1:161-170.[Abstract]
61. Teuliere, J., M. M. Faraldo, M. A. Deugnier, M. Shtutman, A. Ben-Ze'ev, J. P. Thiery, and M. A. Glukhova. 2005. Targeted activation of beta-catenin signaling in basal mammary epithelial cells affects mammary development and leads to hyperplasia. Development 132:267-277.
62. Toda, M., Y. Iizuka, W. Yu, T. Imai, E. Ikeda, K. Yoshida, T. Kawase, Y. Kawakami, H. Okano, and K. Uyemura. 2001. Expression of the neural RNA-binding protein Musashi1 in human gliomas. Glia 34:1-7.[CrossRef][Medline]
63. Toft, D. J., S. B. Rosenberg, G. Bergers, O. Volpert, and D. I. Linzer. 2001. Reactivation of proliferin gene expression is associated with increased angiogenesis in a cell culture model of fibrosarcoma tumor progression. Proc. Natl. Acad. Sci. USA 98:13055-13059.
64. Tsai, R. Y. 2004. A molecular view of stem cell and cancer cell self-renewal. Int. J. Biochem. Cell. Biol. 36:684-694.[CrossRef][Medline]
65. Tsuji, T., I. Nozaki, M. Miyazaki, M. Sakaguchi, H. Pu, Y. Hamazaki, O. Iijima, and M. Namba. 2001. Antiproliferative activity of REIC/Dkk-3 and its significant down-regulation in non-small-cell lung carcinomas. Biochem. Biophys. Res. Commun. 289:257-263.[CrossRef][Medline]
66. van Noort, M., J. Meeldijk, R. van der Zee, O. Destree, and H. Clevers. 2002. Wnt signaling controls the phosphorylation status of beta-catenin. J. Biol. Chem. 277:17901-17905.
67. Volpert, O., D. Jackson, N. Bouck, and D. I. Linzer. 1996. The insulin-like growth factor II/mannose 6-phosphate receptor is required for proliferin-induced angiogenesis. Endocrinology 137:3871-3876.[Abstract]
68. Wakamatsu, Y., T. M. Maynard, S. U. Jones, and J. A. Weston. 1999. NUMB localizes in the basal cortex of mitotic avian neuroepithelial cells and modulates neuronal differentiation by binding to NOTCH-1. Neuron 23:71-81.[CrossRef][Medline]
69. Welm, B., F. Behbod, M. A. Goodell, and J. M. Rosen. 2003. Isolation and characterization of functional mammary gland stem cells. Cell Prolif. 36(Suppl. 1):17-32.[CrossRef][Medline]
70. Welm, B. E., S. B. Tepera, T. Venezia, T. A. Graubert, J. M. Rosen, and M. A. Goodell. 2002. Sca-1(pos) cells in the mouse mammary gland represent an enriched progenitor cell population. Dev. Biol. 245:42-56.[CrossRef][Medline]
71. Wiemers, D. O., L. J. Shao, R. Ain, G. Dai, and M. J. Soares. 2003. The mouse prolactin gene family locus. Endocrinology 144:313-325.
72. Xie, Z., H. Yuan, Y. Yin, X. Zeng, R. Bai, and R. I. Glazer. 2006. 3-Phosphoinositide-dependent protein kinase-1 (PDK1) promotes invasion and activation of matrix metalloproteinases. BMC Cancer 6:77.[CrossRef][Medline]
73. Yin, Y., R. Bai, R. G. Russell, M. E. Beildeck, Z. Xie, L. Kopelovich, and R. I. Glazer. 2005. Characterization of medroxyprogesterone and DMBA-induced multilineage mammary tumors by gene expression profiling. Mol. Carcinog. 44:42-50.[CrossRef][Medline]
74. Yin, Y., R. G. Russell, L. E. Dettin, R. Bai, Z. L. Wei, A. P. Kozikowski, L. Kopelovich, and R. I. Glazer. 2005. Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res. 65:3950-3957.
75. Yokota, N., T. G. Mainprize, M. D. Taylor, T. Kohata, M. Loreto, S. Ueda, W. Dura, W. Grajkowska, J. S. Kuo, and J. T. Rutka. 2004. Identification of differentially expressed and developmentally regulated genes in medulloblastoma using suppression subtraction hybridization. Oncogene 23:3444-3453.[CrossRef][Medline]
76. Zeng, X., H. Xu, B.-K. Park, and R. I. Glazer. 2002. Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 (PDK1) is associated with the induction of protein kinase C
. Cancer Res. 62:3538-3543.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. |
|---|